A senior manager at institute B rang the editor a few days after publication. The manger stated that the original manuscript had been approved for submission by institute B but the revised manuscript had not, and asked the editor to remove the paper from the journal’s website immediately. The editor said that this was not possible and further explained that if institute B wanted the paper retracted then they would need to provide a written justification.
编辑给这件事通过再保险紧急关注viewing the paper and checking the journal’s ethical guidelines (which are those of COPE). They concluded that a retraction was not warranted because the majority of this paper had not changed post revision so the potentially misleading revisions amounted to just a small portion of an otherwise reliable publication. The editor also concluded that, in accordance with COPE guidelines, the authors should submit an erratum detailing the specific passages of text that were incorrect and provide factually correct rewording. The editor sent these conclusions in an email to the manager at institute B the same day and waited for an erratum to be submitted promptly given the apparent seriousness of the situation. The editor did not reveal the names of the referees as the journal operates a closed review process. The editor also alerted the journal’s overseas publisher to this issue in order to fast track the erratum.
编辑提交这个案例是为了强调以下问题: • key stakeholders in a published work (but not the actual authors) have attempted to suppress legitimate scientific results because of possible economic and political damage to an export industry; •这是一个严重的科学伦理; • unfounded allegations have been levelled at the journal’s owner for allowing the paper to be published.
应对论坛的问题
我们建议采取哪些进一步的步骤或替代行动?
建议:
This is essentially a conflict of interest issue, not with the authors, but with the employers/funders, emphasising the ubiquitous nature of conflicts of interest. The editor proposed that having clear guidelines and examples for similar situations from COPE would be helpful to resist pressure from funders or employers.
As the institutions found no evidence of misconduct, and the editor is satisfied with the paper, most agreed that the paper should be published but that the editor should perhaps consult the journal’s legal team and the society's board. All agreed the editor has done all the right things and ultimately it is his decision whether or not to publish. An editor does have a duty to publish good research.
Following the advice from the Forum, the editor has instigated a process whereby there will be footnotes on presentations and special symposium to be published together in an upcoming issue of the journal, which will take the form of: “This paper is based on a presentation at a Special Symposium on (date), (title), for which the presenting author received an honorarium. (Name of Author 1) has consulting and/or financial relationships with (List of Companies whether or not related to study). (Name of Author 2) etc. (Name of Author 3) and (Name of Author 4) have nothing to declare.”
The reviewer was concerned that an attempt was being made to publish data without the approval of the trial sponsors. The editors rejected the paper but recommended that the authors submit it to a sister journal at the same publishing company, but that they would need to address all of the points raised. The paper was then submitted separately to the sister journal but without any response to the reviewer’s points. The authors eventually explained that the patients in this study had been enrolled in an expanded access program for the investigational drug, which was underwritten by governmental sources. This was not regarded as a trial, and the authors explained that gene sequencing was carried out as part of routine clinical care, following national treatment guidelines.
_ Generally drug companies have policies against PR companies approaching journals and if the drug company was identifiable then the editor could contact the company concerned to complain. _ The lead author of the study should be informed about the actions of individuals representing the product being discussed in the paper. _ The drug company might also want to know what the PR is doing on its behalf. One of the members relayed how in a similar circumstance he had complained to the drug company which had withdrawn its contract with the offending PR company.